stooocks.com

Understand any stock in simple English
Enter a ticker to learn what the company does and how it makes money.

Zymeworks Inc.

United States · NASDAQ: ZYME · Market cap: · P/E: · P/S:

Zymeworks designs and develops new kinds of cancer medicines, mainly bispecific antibodies and antibody-drug conjugates, and earns money by partnering with larger drug companies.

Zymeworks is a drug developer that builds a specific kind of cancer medicine: antibodies engineered to do more than one job at once. Its specialty is bispecific antibodies, which are lab-made proteins designed to grab two different targets at the same time, and antibody-drug conjugates, which are antibodies used as guided missiles to carry a toxic payload straight to cancer cells. The idea is to hit tumors harder and more precisely than old-fashioned chemotherapy, while going easier on healthy tissue.

Zymeworks Inc. (ZYME) Ziihera (zanidatamab): line art illustration of a vial of Ziihera medicine with its brand label and a bispecific antibody shape drawn beside it
Ziihera medicine
Ziihera is a bispecific antibody that binds two HER2 sites at once.

The company doesn't mainly sell pills itself. Its money comes from partnerships with bigger drugmakers who license its technology and candidates. The clearest example is zanidatamab, a bispecific antibody for certain cancers that Zymeworks developed and then licensed to Jazz Pharmaceuticals and, in some regions, to BeiGene. Those partners run the costly late-stage trials and handle commercialization, while Zymeworks collects milestone payments and royalties on sales. It also earns fees by letting other companies use its antibody-engineering platforms to build their own drugs. That partnership model is the heart of the business and also its main vulnerability. Zymeworks gets paid when partners succeed, so a lot of its near-term value rides on a handful of collaborations rather than a broad, diversified product line. If a partner's drug stumbles in trials or the partner walks away, the revenue can shrink fast. On the plus side, this approach keeps Zymeworks' own spending lower and spreads its science across many programs, and it has moved to trim costs and focus resources on the bets most likely to pay off.


The company started in Canada and its co-founder, Ali Tehrani, became a well-known figure in the biotech world as chief executive. Today Zymeworks is based in the United States, and it is a clinical-stage biotech: not yet reliably profitable, funding itself through deals and its cash pile. That means the story for investors is less about smooth sales today and more about whether its antibody designs keep winning partnerships and eventually turn into approved medicines.

Saved answer · last researched 16 Nov 2026